Story Stocks^®

The Cooper Companies (COO) is plunging lower after a Q3 revenue miss and sharply downside Q4 guidance exposed a steeper near-term slowdown at CooperVision, while the completed strategic review ended without a sale of CooperSurgical. Q4 guidance calls for adjusted EPS of $1.05-$1.09 versus the $1.19 FactSet consensus and revenue of $1.057-$1.080 bln versus $1.11 bln, outweighing healthy U.S. consumption, record free cash flow and expanded repurchase capacity.

• Management attributed the reduction in its second-half CooperVision revenue forecast entirely to accelerated U.S. destocking, noting that Americas growth would have been approximately 5% without the inventory action. COO is roughly halfway through the correction and expects a similar Q4 drag, but it must also complete legacy-hydrogel rationalization and improve contract-to-revenue conversion.
• Gross margin declined 60 bps to 66.7%, while productivity lifted operating margin 30 bps to 26.3%. Adjusted EPS included approximately $0.03 from tariff refunds, and Q4 profitability will face increased CooperVision commercial investment, unfavorable FX, lower tariff refunds and reduced volume leverage.
• CooperVision’s underlying demand remained healthy, with MiSight growing 20% organically and MyDay posting double-digit growth in EMEA and double-digit consumption growth in the Americas. However, limited participation in super-premium daily lenses, softness in China and insufficient U.S. sales coverage remain structural constraints. New representatives are unlikely to contribute meaningfully until 2H27.
• The board retained CooperSurgical after bids failed to reflect its perceived value, with the new non-hormonal IUD competitor and fertility litigation settlement temporarily weighing on offers. CooperSurgical grew 3% organically, including 5% fertility growth, but retaining the business removes a near-term transaction catalyst and increases the importance of delivering returns from fertility and R&D investment.
• Free cash flow reached a quarterly record of $273 mln and totaled $528 mln year to date, up 86%, supporting $339 mln of Q3 repurchases and approximately $1.5 bln of remaining authorization. COO also resolved a UK tax examination favorably, but its normalized tax rate is expected to increase from approximately 15.5% to 17.5% in FY27 because of GILTI changes.

Briefing.com Analyst Insight

The sharp reset reflects more than a temporary mismatch between contact-lens consumption and reported revenue. COO is deliberately removing excess inventory before FY27, but management also acknowledged that an undersized sales force, uneven commercial execution and gaps in premium daily lenses have prevented contract wins and patient growth from producing adequate revenue. That makes the recovery dependent on both completing the destock and improving CooperVision’s underlying competitive execution. Strong MiSight and MyDay trends, productivity gains and substantial cash generation provide support, but new sales investments will pressure near-term margins before producing meaningful benefits. The decisive FY27 measures will be market-level CooperVision growth, improved revenue conversion and enough operating leverage to absorb the higher tax rate.